Following the completion of the proposed merger between Oxford GlycoSciences (OGS) and Cambridge Antibody Technology (CAT), both based in the UK, CAT will continue to be chaired by Peter Garland. Peter Chambré will remain CEO and John Aston CFO of the merged company.
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
Not ready for premium?
Register for Free ContentYou can still register for access to our free content.